1. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma 
Lorenzo Falchi, Alessandra Ferrajoli, Ira Jacobs, Pilar Nava-Parada 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 18, Issue 8, Pages e14 (August 2018)
DOI: /j.clml
Copyright © 2018 Elsevier Inc. Terms and Conditions

2. Figure 1
Reported Overall Response Rate (ORR) for Patients With Relapsed or Refractory (A) Chronic Lymphocytic Leukemia (CLL), (B) Follicular Lymphoma (FL), or (C) Diffuse Large B-cell Lymphoma (DLBCL). Data Points Represent Reported ORR for Each Study, Stratified by Drug Regimen and Median Patient Age. ORR Data Were Reported in 25 Studies for Rituximab Across All 3 Diseases, 10 Studies for Ofatumumab, and 1 Study for Obinutuzumab. Several Studies Reported Data for > 1 Anti-CD20 Combination or Disease. Thus, the Data Points Will Not Correspond to the Total Number of Studies Reporting ORR Data
Abbreviations: B = bendamustine; B-Ibr = bendamustine, ibrutinib; B-idela = bendamustine, idelalisib; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisolone; Clb = chlorambucil; Dex = dexamethasone; DHAP = dexamethasone, high-dose cytarabine, cisplatin; ESHAP = etoposide, methylprednisolone, cytarabine, cisplatin; F = fludarabine; FC = fludarabine, cyclophosphamide; FCM = fludarabine, cyclophosphamide, mitoxantrone; FM = fludarabine, mitoxantrone; Ibr = ibrutinib; ICE = ifosfamide, carboplatin, etoposide; Idela = idelalisib; Ven = venetoclax.
Clinical Lymphoma, Myeloma and Leukemia  , e14DOI: ( /j.clml )
Copyright © 2018 Elsevier Inc. Terms and Conditions